Luque, M.; Sanz-Álvarez, M.; Santamaría, A.; Zazo, S.; Cristóbal, I.; de la Fuente, L.; Mínguez, P.; Eroles, P.; Rovira, A.; Albanell, J.;
et al. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. Int. J. Mol. Sci. 2021, 22, 13297.
https://doi.org/10.3390/ijms222413297
AMA Style
Luque M, Sanz-Álvarez M, Santamaría A, Zazo S, Cristóbal I, de la Fuente L, Mínguez P, Eroles P, Rovira A, Albanell J,
et al. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. International Journal of Molecular Sciences. 2021; 22(24):13297.
https://doi.org/10.3390/ijms222413297
Chicago/Turabian Style
Luque, Melani, Marta Sanz-Álvarez, Andrea Santamaría, Sandra Zazo, Ion Cristóbal, Lorena de la Fuente, Pablo Mínguez, Pilar Eroles, Ana Rovira, Joan Albanell,
and et al. 2021. "Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer" International Journal of Molecular Sciences 22, no. 24: 13297.
https://doi.org/10.3390/ijms222413297
APA Style
Luque, M., Sanz-Álvarez, M., Santamaría, A., Zazo, S., Cristóbal, I., de la Fuente, L., Mínguez, P., Eroles, P., Rovira, A., Albanell, J., Madoz-Gúrpide, J., & Rojo, F.
(2021). Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 22(24), 13297.
https://doi.org/10.3390/ijms222413297
